Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Anti dumping duty...

    Anti dumping duty imposed on Ofloxacin import from China

    Written by Ruby Khatun Khatun Published On 2018-03-19T10:15:50+05:30  |  Updated On 19 March 2018 10:15 AM IST
    Anti dumping duty imposed on Ofloxacin import from China

    New Delhi: India has imposed anti dumping duty on import of Chinese pharma product, used in the treatment of certain infections, to protect domestic producers from below-cost shipments.


    The duty on import of 'Ofloxacin' from China will be in the range of USD 2.58 to USD 9.48 per kilogram for three years, said a notification issued by the revenue department in the finance ministry.


    The levy has been slapped following the recommendations of the Directorate General of Anti-Dumping and Allied Duties (DGAD).


    Aarti Drugs had approached the DGAD for initiation of anti-dumping investigation and imposition of the duty concerning imports of Ofloxacin, originating in or exported from China.


    After a probe into the imports, the Authority concluded that the product has been exported to India from China below its normal value, "resulting in dumping".


    "The domestic industry has suffered material injury due to dumping of the product...," the DGAD said while recommending the levy.


    Ofloxacin is used to treat certain infections including bronchitis, pneumonia, and infections of the skin, bladder, urinary tract, reproductive organs, and prostate (a male reproductive gland).


    Ofloxacin is in a class of antibiotics called fluoroquinolones. It works by killing bacteria that cause infections.


    Countries carry out the anti-dumping probe to determine whether their domestic industries have been hurt because of a surge in imports which are below the cost of producing them.


    As a counter measure, they impose duties under the multilateral regime of WTO.


    The duty is aimed at ensuring fair trading practices and creating a level-playing field for domestic producers with regard to foreign producers and exporters.

    Aarti DrugsAnti-dumping dutyantibioticsbronchitischinaDGADDirectorate General of Anti-Dumping and Allied DutiesfluoroquinolonesimposedinfectionsOfloxacinOfloxacin importPneumoniaWTO
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok